Drug Trial Radar · NCT05369286
A Study to Evaluate the Safety and Efficacy of Max-40279 and Toripalimab in Patients With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: May 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
28
Planned (sponsor's estimate)
Start
Apr 11, 2022
Primary completion
May 31, 2023
Study completion Aug 31, 2023
Sponsor
- Lead sponsor
- Maxinovel Pty., Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 11, 2022
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This include two parts, part 1 is a dose escalation study and part 2 is a dose expansion study.
Conditions
- Solid Tumor
Interventions
"MAX-40279-01" and "Toripalimab"Drug
"MAX-40279-01"combined with "Toripalimab"
Primary outcomes
What the sponsor says the trial is designed to measure.
- DLTsTime frame: 21 days
- Incidence of Treatment-Emergent Adverse EventsTime frame: 24 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Institute of The Sixth Affiliated Hospital Sun Yat-sen University
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.